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INTRODUCTION
Hypertensive disorders complicates about 5-10% of pregnancies.
It is the third  most common cause for maternal and fetal morbidity and
mortality. It is one among the  triad which causes maternal mortality, like
that of along hemorrhage and infection. Hypertension and proteinuria are
minimum criteria to diagnose preeclampsia. Proteinuria is called
significant when there is excretion of more than or equal to 300 mg of
urinary protein in 24 hrs period.
Proteinuria is a marker that indicates system wide endothelial
leaks. Abnormalities in the angiogenic balance play a important role in
the cascade of events leading to protein excretion, hypertension and
endothelial dysfunction.
Even though 24 hrs urine collection is the Gold standard for the
diagnosis of significant proteinuria, Spot urine protein - creatinine ratio is
a more rapid and convenient method to detect protein excretion. It avoids
the influence of variations in urinary solute concentration. Therefore it is
an accurate test and provides efficient in-patient and out-patient
monitoring.
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Berg and Colleagues (2003) reported that about16% of maternal
deaths are due to complications related to preeclampsia and more than
half of it are preventable.
Therefore  prediction of preeclampsia in early gestation is of
utmost importance to detect and to intervene in the management of high
risk pregnancies much earlier to reduce the maternal death and fetal
mortality and neonatal morbidity.
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REVIEW OF LITERATURE
Hypertension is one of the most common medical disorders
complicating pregnancy. In India it is the second most common condition
that complicates pregnancy, next to anemia. Preeclampsia is a
multisystem disorder which occurs after 20 weeks' of gestation that
results in widespread vascular endothelial malfunction and vasospasm.
The normal physiological changes in pregnancy causes reduced vascular
tone and low periperal vascular resistance which reduces the maternal
blood pressure as early as 7 wks of gestation .It reaches a nadir at 16 to
20 wks of gestation, and increases after 28 wks to reach the  pre-
pregnancy level before term.
 Hypertension is defined by the International Society for the study
of Hypertension in pregnancy (ISSHP) as, a  blood pressure more than or
equal to 140/90 mm Hg, recorded 4-6 hrs apart.
Classification:
The Working group classification of Hypertensive disorders,
classifies hypertensive disease as,
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a) Gestational hypertension
b) Preeclampsia and Eclampsia syndromes
c) Preeclampsia superimposed on chronic hyprtension
d) Chronic hyprtension
? Gestational hypertension is defined as blood pressure 140/90mm
Hg  and  above,  diagnosed  for  the  first  time  after  20  wks  of
gestation, without proteinuria and the blood pressure recording
comes to normal within  12 weeks  duration of postpartum period .
It is a diagnosis of exclusion. About half of these patients develop
preeclampsia syndrome later.
? Preeclampsia syndrome is specific to pregnancy  that affects almost
every organs. Its adverse outcome is reflected by the severity of the
hypertension and proteinuria.
? Eclampsia is onset of seizures that occur in a case of preeclampsia
that cannot be attributed to any other cause.
? Preeclampsia superimposed on chronic hyprtension:
? This term is defined as new onset proteinuria or when the  blood
pressure suddenly increases or poteinuria occurs in  chronic
hypertensive women.
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? Chronic hypertension:
          Chronic hypertension can be defined as presence of hypertension
prior to pregnancy or hypertension which was diagnosed prior  20 weeks
of pregnancy, but not due to gestational trophoblastic disease.
Hypertension  which was first detected after 20 weeks & persisting even
after 12 weeks postpartum is also considered as chronic Hypertension.
* Epidemiology
Pre-eclampsia which is a multisystem disorder complicates about
3%–8% of pregnancies in Western countries. About 10%–15% of
maternal mortality are directly related with pre-eclampsia syndrome and
eclampsia. There is 2-fold to 5-fold risk of pre-eclampsia in pregnant
women with a maternal history. The incidence of pre-eclampsia occirs in
about 3% to 7% of nulliparas women and 1% to 3% of multiparas
women. Nulliparity and exposure to a new partner are the important risk
factors.
? The risk factors of Preeclampsia  includes
? African American ethnicity
? Nulliparity
? Extremes of age with more risk in teenege pregnancy
? With  history of preeclampsia in previous pregnancy
? Family history suggestive of preeclampsia
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16
? Obesity
? mutiple pregnancy,hydrops fetalis,hydatiform mole
? Preexisting medical disorders like diabetes, kidney disease, lupus,
or rheumatoid arthritis,thrombophilias
? Environmental factors
? Etio Pathogenesis
* Preeclampsia occurs due to culmination of maternal, placental and
fetal factors which includes,
* Incomplete invasion of the uterine vessels by the trophoblastic
cells.
* Maladaptive immunological tolerance appearing between
maternal, placental and fetal component.
* Maladaptation to normal physiological changes in the
cardiovascular system and inflammatory changes that occurs in
pregnancy.
* Genetic predisposition
* The exact etiology is not known.There are various theories
proposed but the two major ones are:
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a) Abnormal trophoblastic invasion
b) Endothelial cell dysfunction
a) Abnormal Trophoblastic Invasion:
Placenta is the inciting factor responsible for preeclampsia-
eclampsia syndrome. In  normal pregnancy, the villous cytotrophoblastic
cells  invades upto  the inner third portion of the myometrium, and in the
spiral arteries, there is  loss of endothelial layer and  their muscle fibers
are replaced by cytotrophoblast. These modifications makes the spiral
arteries as low-resistance vessels, and thus render them less sensitive, or
even insensitive, to vasoconstrictive substances.
This process begins around 10-12 wks of gestation and completed
by 18 -20 wks of gestation.
In preeclampsia, due to incomplete trophoblastic invasion, the
deeper myometrial arterioles does not lose their musculoelastic tissue and
endothelial lining. Therefore the external diameter of the vessels is only
half that of vessels when compared to the vessels in normalplacenta.
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FIGURE - 1
TROPHOBLASTIC INVASION OF IN NORMAL PLACENTA
AND IN PREECLAMPSIA
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The impaired  placental  blood flow through the narrow spiral
arterioles leads to diminished perfusion and hypoxic environment which
in turn releases cytokines and vasoactive substances leading to systemic
inflammatory response that leads to cascade of events to provoke
endothelial cell injury.
FIGURE - 2
 EFFECT OF VASOACTIVE SUBSTANCES IN PREECLAMPSIA
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20
? Endothelial cell activation
* Defective placentation causes release of cytokines such as tumour
necrosis factor (TNF-alpha), and interleukins (IL) leads to the
formation of reactive oxygen species and free radicals which
injures the endothelial cells and modifies its nitric oxide production
and prostsglandin balance. It also leads to the production of lipid
laden macrophages and formation of atherosis and initiates
microvascular coagulation cascade and it is manifested as
thrombocytopenia. Increased capillary permeability resuts in
edema and proteinuria.
* Pre-eclampsia may results in  impairment of the immune system of
the mother which prevents it to recognise the fetoplacental unit,
high production of immune mediated cells causes the production of
tumor necrosis factor alpha, which may  induce apoptotic death of
the extravillous cytotrophoblast.
* The human leukocyte antigen (HLA) system also plays an
important a role in the incomplete invasion of  spiral arteries, in the
women affected by pre-eclampsia, and they show decreased levels
of HLA-E and HLA-G.
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* In  normal pregnancies, the interaction between these cells and the
trophoblast is due to secretion of vascular endothelial growth factor
and the placental growth factor, by natural killer cells.
* Increased secretion of soluble fms-like tyrosine kinase 1 (sFlt-1) an
antagonist of vascular endothelial growth factor and placental
growth factor, have been found in women with pre-eclampsia.
Assays of sFlt-1, placental growth factor, endoglin, and vascular
endothelial growth factors  increases about 4–8 weeks before the
onset of the disease. These factors may be used as predictors of
pre-eclampsia.
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FIGURE -  3
PATHOGENESIS OF PREECLAMPSIA
* Latest data show the protective effect of heme oxygenase 1 and its
byproduct the carbon monoxide, and its positive effect in
pregnancy, and identified these products as a potential target in the
treatment of  patients with pre-eclampsia.
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* Pathophysiology
* As a consequence of vasospasm, endothelial dysfunction and
ischemia, preeclampsia affects multiorgan systems.
FIGURE – 4
 ETIOLOGY AND EFFECTS OF PREECLAMPSIA
? Cardiovascular system:
? Hypertension increases preload and afterload. Endothelial
activation leads to extravasation of intravascular fluid to
extracellular space.
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? Endocrine System:
? Elevated blood pressure and increase in vascular resistance seen in
preeclampsia is due to interference in the  sensitivity of the vessels
to endogenous hormones like angiotensin II, vasopressin and
catecholamines. There is refractoriness to the pressor effect of
angiotensin II in normal pregnancy.
FIGURE – 5
RENIN – ANGIOTENSIN – ALDOSTERONE SYSTEM
In preeclampsia there is increased vascular reactivity to these
pressor hormones.
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FIGURE – 6
EFFECT OF GENETIC FACTORS ON PREGNANCY
? The abnormal sensitivity occurs between  17 weeks and the clinical
onset of gestational hypertension.
? Gant and colleagues reported that loss of refractoriness to
angiotensin II occurs 8 to 12 weeks before the onset of the clinical
manifestations of gestational hypertension.
? Platelets and trophoblasts produces Thromboxane A2, which is  a
potent vasoconstrictor and platelet aggregator.
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? In preeclampsia, the ratio between thromboxane A2 and
prostacyclin increases thus decreaseing placental production of
prostacycline.
? In gestational hypertension, the prostacyclin metabolite, 6-keto-
prostaglandin F1? decreases in maternal, placental, and umbilical
vessels.
? Hematological System:
? The hemoconcentration seen in gestational hypertension leads to
decreased regional perfusion.
? Due to increase in the vascular tone and vasospasm in
preeclampsia, in the absence of hemorrhage, the intravascular
compartment is not underfilled.
?  Hematocrit increases with increased severity of gestational
hypertension.
? Vascular spasm and hemoconcentration results in the reduction in
the intravascular space in patients with preeclampsia.
? The vasospasm, result in endothelial injury. Dadak and associates
detected marked damage to the endothelium of the umbilical
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arteries of mothers with gestational hypertension which could be
the cause of the microangiopathic hemolysis.
? Gestational hypertension is found to be associated with high levels
of fibronectin, low levels of antithrombin III and ?2-antiplasmin.
? Changes in the levels of these factors helps to diagnose
preeclampsia and to differentiate it from chronic hypertension.
? Placenta
o Placenta shows features of infarcts, hematomas, proliferative
endarteritis and degeneration.
o Preeclampsia causes atherosis, fibrinoid necrosis, mononuclear and
macrophage cell infiltration.
? Kidney
Glomerular capillary endotheliosis, is the characteristic renal lesion
seen in preeclampsia.
- Light microscopy Examination of the preeclamptic kidney shows
prominence of endocapillary (mesangial and endothelial) cells.
- There was also  infiltration of macrophages, lymphocytes and
polymorphonuclear leukocytes within capillary lumens. The
hypertrophy of endothelial cells, results in loss of capillary
patency.
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- There was variable thickening of glomerular capillary walls,
related to mesangial interposition, and prominent subendothelial
hyaline deposits.
-  Transmission electron microscopy showed features of endothelial
cell hyperplasia, and exudation of foamy macrophages,
lymphocytes, and polymorphonuclear leukocytes within the
capillary lumina and mesangium.
- The lesions resolves completely after delivery.
? Liver
o The changes that occurs in preeclampsia are periportal
haemorrhages, fibrin deposition and ischemic lesion.
o Liver damage ranges from mild hepatocellular necrosis to very
severe liver injury which increases liver enzymes.
o It also causes subcapsular rupture.
Brain –Cerebral blood flow and  oxygen metabolism in brain are
usually unaltered. There is an increase in the cerebrovascular accidents in
preeclampsia when compared with normal pregnancy. CT Brainshows
multiple petichial haemorrhages, in the cortex, pons and midbrain.
Eventhough  60 % of  women developing eclampsia,is complicated with
intracerebral bleeding, it causes only 50% of maternal mortality.
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
29
? Clinical presentation:
Preeclampsia syndrome shows severe neurological manifestations
every complication needs immediate attension.
1. Headache / scotomata :  occurs  due  to   hyperperfusion  of  the
cerebral vessels, more commonly involving  the occipital lobes.
Headaches  is  seen  in  50  %  to  75%  of  women  with  preeclampsia
and 20 to 30 percent have  changes in the vision  eclamptic seizures
occurs. The headaches present as mild to severe. The headache
may be intermittent, or present constantly. magnesium sulfate.
administration usually reduces headache and visual disturbances.
2. Convulsions which is the diagnostic feature of eclampsia.
3. Blindness is present in about  15 percent of women  with eclampsia
and is rarely present in preeclampsia. Blindnesscan occur even one
week after  delivery.
4. Generalized cerebral edema –present as changes in the mental
status. Clinically it presents as confusion to the stage of coma. This
is dangerous, because it may lead to supratentorial herniation and
death.
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? Eyes
The commonest finding is localised retinal vasospasm. Retinal
Haemorrhages and papilloedema  may be seen in severe cases.
Retinal artery ischemia or infarction, are the causes of blindness in
preeclampsia.
? Heart
Subendocardial petichial haemorrhages and acute left ventricular
failure due to left ventricular dilatation.
FIGURE  – 7
PATHOPHYSIOLOGY OF PREECLAMPSIA
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o Criteria to Diagnose Severe Preeclampsia:
o  Systolic blood pressure more than or equal to 160 mmHg or more
than or equal to 110 mm Hg of diastolic pressure.
o Protein excretion > 5 g  in 24 hours or >2+ dipstick
o Severe, Persistent cerebral or visual disturbances (headache,
scotoma, blurred vision)
o Persistent and severe right upper quadrant pain or epigastric pain
o Increased LDH-due to microangiopathic hemolysis
o Platelet count <1,00,000 lakh/ml
o Elevated serum AST, ALT levels.
o Complications:
- Severe maternal complications that occurs in preeclampsia
includes.
- Eclampsia – the seizures that occurs due to increased intracranial
blood pressure resulting in cerebral hemorrhage as a consequence
of rupture of cerebral blood vessels which is the  major cause of
maternal death.
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- Blindness due to retinal detachment
- Abruptio placentae -. The bleeding may  endanger the life of both
the mother and the fetus. Abruptio placentae may result in renal
failure.
HELLP syndrome : HELLP Syndrome: indicates Hemolysis,
Elevated Liver Enzymes, Low Platelets. Hemolysis due  to
destruction of red blood cells. Elevated liver enzymes indicates
inflamed or overactive liver. Low Platelets causes hemorrhage,
especially in the brain.
Differential Diagnosis are.
? Hepatitis, cholecystitis, acute fatty liver of pregnancy,
thrombocytopenic purpura (TTP)
? 20% of  HELLP syndrome occurs in the  postpartum period
? Peak time of occurence is 24-48 hrs after delivery.
? 50% of the affected women have nausea and vomiting.
? When it occurs in the postpartum period, HELLP syndrome is
more fatal and leads to pulmonary edema and renal failure.
o Left ventricular failure.
o Disseminated intravascular coagulation
o Acute pulmonary edema
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? Fetal complications:
o Intrauterine fetal growth restrictions
o Intrauterine asphyxia
o Premature delivery
o Intrauterine fetal death
o Neonatal asphyxia
o Mental retardation
? Predictors of Preeclampsia:
There are various clinical, biophysical and biochemical markers for
prediction and early detection of preeclampsia.
? Isometric exercises:
During the handgrip test, increase in systolic pressure by 15 mm
Hg predicts development of gestational hypertension with sensitivity of
81.8% and specificity of 68.4%
? Roll over test:
Gant  et  al  reported  that,  at  18-22  wks  of  gestation,  when  the
diastolic blood pressure rises by 20 mm Hg or more within 5 minutes
after changing to supine position from left lateral position.
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? Uterine artery Doppler study:
Persistence of diastolic notching after 24 wks of gestation predicts
development of preeclampsia.
? Angiotensin Sensitivity test
- It is based on the theory that loss of  refractoriness to angiotensin
II, between  28-32 weeks of gestation, develop pre-eclampsia later.
- In normal pregnancy, the patient requires mean angiotensin II
doses of 13.5 to 14.9 ng/kg/minute to raise the diastolic  pressure
by 20 mm Hg.
- About Ninety-one percent of women remained normotensive
throughout pregnancy and they required more than 8 ng/kg/minute
to achieve this blood pressure elevation.
? Serum Uric Acid estimation:
- Increased serum uric acid level is  one of  the earliest laboratory
manifestations of preeclampsia (Powers and associates, 2006).
- Due to reduced glomerular filtration, increased tubular
reabsorption, and decreased secretion uric acid clearance reduces
(Lindheimer and colleagues, 2008a).
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
35
- Cnossen and associates (2006) reported  its sensitivity of about 0 to
55 percent and specificity of about 77 to 95 percent.
? Microalbuminuria
Conde-Agudelo and associates (2009), reported sensitivity of about
7 to 90 percent and specificity of about 29% and 97 % and it indicated a
poor clinical predictive value.
? Free Fetal DNA:
- Free fetal DNA  in maternal plasma was detected by polymerase
chain reaction. It was reported by, Lo and colleagues in 1997and
Holzgreve and associates in 1998, that fetal-maternal cell
trafficking is increased in  preeclampsia.
- It is reported that free DNA is released by accelerated apoptosis of
cytotrophoblasts.
- Conde-Agudelo and associates (2009) reported that free fetal DNA
quantification is not useful to predict preeclampsia.
? Other biophysical and biochemical markers are,
? Elevated levels of inhibin A, activin A, serum alpha-fetoprotein,
humanchorionic gonadotropin.
?  Decreased level of placental growth factor in the second trimester.
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? Increased solublefms-like tyrosine kinase-1insecondtrimester.
?  Elevated levels of soluble endoglin in second trimester.
?  Rise in asymmetric dimethyl arginine in second trimester.
?  Decreased serum placentalprotein-13 in the first trimester.
?  Reduced pregnancy associated plasma protein A in first trimester.
? Normal Renal Adaptation in Pregnancy
o In order to accommodate the demands of the fetoplacental unit,
normal pregnancy is characterized by  changes in almost every
organs.
o Pregnancy affects both the kidney and the urinary tract.
o There is increase in size of both the kidneys by about  1 to 1.5 cm
length during pregnancy. The volume of the kidney  increases by
about 30 %,  as a result of  increase in vascular and interstitial cell
volume of the kidney.
o The glomerular filtration rate is also increased by 40%-60%,
leading to increase in creatinine clearance to about 150 to 200 mg /
min, which decreases creatinine level in serum from 0.8 mg/dl to
0.5 mg to 0.6 mg/dl. Therefore non pregnant level of 1.0 mg/dl,
reflects renal impairment in pregnancy.
o Hyperfiltration results primarily from decreased plasma hydrostatic
pressure  in the  capillaries of the glomerulus.
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o The reduction in oncotic pressure is due to two mechanism in
pregnancy.
o The first is due to hemodilution, which is due to hypervolemia, that
lowers the  concentration of the protein in the plasma that flows
through the glomerular microcirculation.
o The second one, due to raise in Renal plasma flow. Hyperperfusion
of the glomerular capillaries reduces the extent to which the
hydrostatic pressure can increase along the glomerulus in the
process of filtrate formation.
o The renal pelvises and calyces are dilated due to the effect of
progesterone and  compression of the ureters in the region of pelvic
brim.
o Ureters — on the right side, Hydroureter and hydronephrosis is
more prominent than the left and is present in about 80 percent of
pregnant women. These changes are visualized on ultrasound
examination from the second trimester, and does not reverse to
normal until after 6 to 12 weeks postpartum.
o There are no changes in number of nephrons or histological
changes do not occur.
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o In preeclampsia, there are variable degrees of insufficiency of the
renal system associated with “glomerular endotheliosis”,
characteristic lesion of the glomerulus, in preeclampsia
o In patients with preeclampsia, decrease in the density and the size
of the endothelial fenestrae and  there is subendothelial deposition
of  fibrinoid material decreases glomerular hydraulic  permeability.
Mesangial cell interposition also reduces the  available surface area
for filtration,  leading to reduction in  GFR.
o The basis for the hypofiltration in patients with preeclampsia is due
to structural changes in the glomerulus as opposed to
vasoconstriction of the renal vessels and a redution in renal plasma
flow.
o Proteinuria:
o In 1843,  it was, John Lever of Guy's Hospital from London, first
discovered the presence of albumin in the urine of the pregnant
women with puerperal convulsions.
o Proteinuria differentiates preeclampsia from gestational
hypertension.
o The amount of protein excretion in the urine varies widely.
Significant proteinuria is defined as ?300 mg in a 24-h urine
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collection or 1+ or more on   testing the two random urine samples
by dipstick method. Two samples should be collected at least 4 hrs
apart but  not more than 7 days.
o According to ACOG Guidelines, the diagnosis of Preeclampsia is
excretion of >300 mg protein in 24 hrs urine collection.
o Excretion of intermediate size Glomerular proteins, like that of
albumin, either identified alone or in combination with  tubular
proteins, like B2-microglobulin, reflects the tubular destruction that
can occur in severe preeclampsia.
o Protein excretion in preeclampsia range from minimum to
nephrotic range.
o Eventhough 24 hrs urine protein is the gold standard method, the
urine protein to creatinine ratio is considered as preferred method
for quantification of proteinuria, due to inconvenience to the
patient to collect 24 hrs urine collection, and due to under
collection and  delayed result.
o When the GFR is stable, the excretion of protein and creatinine  is
almost constant  throughout the day.
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o Variation in the protein and albumin excretion in urine samples
collected throughout the day are lesser when their concentrations
are expressed as a ratio to creatinine or specific gravity.
o The primary cause of defect in the glomerular filtration barrier in
patients with preeclampsia, is loss of charge selectivity.
o Borderline proteinuria (250 to 400mg / day) leads to
misclassification. Therefore  it is advisable to use the P/C RATIO
to predict the occurrence of  preeclampsia.
o A  Study conducted in 2008 found that sensitivity of P/C Ratio is
66% when compared to Dipstick  method which is 41%.
o P/C Ratio also predicted presence or absence of proteinuria which
is 64% when compared to Dipstick method which predicted only
19%.
o Therefore P/C Ratio is a better screening tool as well as excellent
alternative to cumbersome 24 hour urine collection.
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? Management:
The main goals of treatment are:
? To prevent convulsions
? To protect the patients from complications, such as cerebrovascular
hemorrhage, pulmonary edema, renal failure, abruptio placentae,
and fetal death,
? To deliver a healthy baby with minimal trauma to the mother.
? Mild preeclampsia :
? Hospitalization is usually advisable for patients with preeclampsia
who are diagnosed for the first time.
? Monitoring of maternal condition and fetal condition is essential,
even in patients with mild preeclampsia, who  can be treated on an
outpatient basis .
? When the patient is compliant, and with immature fetus, she can be
treated as out patient with careful maternal and fetal monitoring.
? She should be adviced to visit every fortnightly. She should be
explained about the severity of preeclampsia and about the
imminent symptoms.
? At each visit, her blood pressure, urine for protein and fetal
wellbeing should be monitored.
? When the patient is non-complaint, she should be hospitalized.
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? Maternal monitoring:
? Regular diet without  salt restriction
? Blood pressure monitoring-4 times daily
? Urine protein daily
? Daily monitoring of weight
? Watch for imminent symptoms
? Check twice weekly- peripheral smear, platelet count, renal and
liver function tests, uric acid, coagulation profile.
? Fetal surveillance:
? The frequency of monitoring depends upon the severity of the
disease and presence of IUGR
? Daily fetal kick count monitoring
? NST and amniotic fluid volume assessment
? Ultrasound  assessment of fetal growth and well being
? Doppler velocimetry in IUGR
? Antihypertensives:
? Careful monitoring and control of hypertension is necessary, to
protect the patients from complications, such as maternal
cerebrovascular accidents and  abruption placenta.
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? Antihypertensive treatment is usually started when systolic blood
pressure exceeds 160 mm Hg or diastolic blood pressure is  equal
to or more than 110 mm Hg.
? The commonly used antihypertensives are alpha methyl dopa,
nifedipine and labetolol.
? Labetalol, which is a combined ?- and ?-adrenoreceptor antagonist,
is used to induce a controlled and rapid decrease in blood pressure
by reducing systemic vascular resistance in patients with severe
hypertension.
? There are favorable studies, on the efficacy and safety of labetalol
to treat hypertension complicating pregnancy.
? Mabie and colleagues, studied comparison between bolus dose of
intravenous administration of labetalol with intravenous
hydralazine, in the emergency management of severe hypertension.
? The results of the study showed  that the drug  labetalol had a more
rapid onset of action and there was no reflex tachycardia.
? Other effects of Labetalol are ,it has a positive effect on early fetal
lung maturation.
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? Lunell and associate reported increased uteroplacental perfusion
and decreased uterine vascular resistance after the use of  labetalol.
? Labetalol is administered parenterally as intravenous injection or
slow continuous infusion.
? In intravenous injection, an initial dose of 20 mg is administered
and additional doses of 40 to 80 mg at  intervals of 10-minutes,
until the desired effect is achieved can be given if required. A total
of 220 mg can be administered.
? If  continuous infusion is used, labetalol is started at a dose of 2
mg/minute. Maximum effect is achieved about 5 minutes after
intravenous administration.
? Oral dosage of labetalol can be given as 100 mg twice daily.
Maximum dose of 2400 mg/day can be given.
o Nifedipine is started as a oral dose of 10 mg. It  can be given orally
again after 30 minutes, for the acute emergency management of
severe hypertension; after that 10 to 20 mg may be administered
orally every 6 to 8 hours, if needed.
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* Role of MGSO4:
* Magnesium Sulfate is the dug of choice to Control Convulsions.
* It Acts as a vasodilator in cerebral vessels and menbrane stabilizer
* Loading dose of 4 grams diluted in 12 ml distilled water or with
normal saline is given slow iv over 20 min and  maintenance dose
is continued every 4 hrs, till 24 hrs postpartum or from  last fit
whichever is later.
* Over  dose  of  MgSO4  lead  to   depression   of  respiratory  system
and cardiac arrest.
* Deep tendon reflexes, respiratory rate and urine output should be
monitored to continue the next dose.
* Antidote-10 ml of 10% solution of  calcium. Gluconate should be
given in over dosage. Therapeutic dose should be maintained
between 4-7 mq/l.
? Mode of delivery:
? The only cure for patients with preeclampsia is termination of
pregnancy.
? When the fetus is immature, well-being of the fetus  and placental
function should be assessed, to prolong the pregnancy  for a few
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weeks more in utero which reduces the risk of  morbidity and
mortality of the  premature neonates.
? In case of severe preeclampsia without control of blood pressure
after admission, termination of pregnancy is advisable for the sake
of both mother and baby. Labor induced with preinduction cervical
ripening with a prostaglandin or osmotic dilator. In case of failed
induction, cesarean delivery is indicated.
? In patients with preeclampsia in term gestation, with controlled
blood pressure, should have a trial of vaginal delivery.
? For the patient near term with soft, partially effaced cervix, even in
milder degrees of preeclampsia the risk to the mother and her fetus
is high.
? Barton and colleagues (2009) reported that there is excessive
neonatal morbidity in women delivered before 38 weeks of
gestation even when the patient is with mild nonproteinuric
gestational hypertension.
? Expectant management:
? In severe preeclampsia remote from term, "conservative" or
"expectant" management is adviced to improve neonatal outcome
without compromising maternal safety.
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
47
? Expectant management  includes, careful daily  monitoring of the
woman and fetus, with or without antihypertensive drugs.
? Expectant management is not followed in women with HELLP
syndrome or  fetus with growth restriction.
? Expectant Management of Severe Preeclampsia in
Midtrimester:
? There are various studies about expectant management of  patients
with severe preeclampsia syndrome before 28 weeks.
? There were no live infants delivered before 23 weeks.
? Neonates delivered at 23 weeks, the perinatal survival rate was 18
percent, but long-term perinatal morbidity is not yet known.
? When terminated at 24 to 26 weeks, perinatal survival rate was 60
percent, and the survival rate for women delivered at26 weeks is
almost 90 percent.
? Glucocorticoids for Lung Maturation:
? Glucocorticoids  are given to women with severe hypertension who
are remote from term to enhance fetal lung maturation.
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? It also reduces the incidence of respiratory distress, intraventricular
hemorrhage, and death. (Bloom and Leveno, 2003; Leveno and
Cunningham, 2009).
o Indications for immediate termination of pregnancy:
o Maternal indications
? imminent symptoms, such as  severe headache or blindness
? Patients with Shortness of breath, pulmonary edema
? Uncontrollable  severe hypertension inspite of management with
antihypertensives
? Serum creatinine level > 1.5 mg/dL
? Decreased urine output < 500 mL/24 hr
? Persistent thrombocytopenia < 100,000/l
? Suspected case of  abruption
? Abnormal renal function or liver function tests or coagulation
disorder.
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Fetal indications
Severe  intrauterine growth restriction—< 5th percentile for EGA
Persistent reduced liquor—AFI < 5 cm
Biophysical profile score <=4 ,assessed 6 hrs apart
Reversed end-diastolic umbilical artery flow in Doppler study
Anesthesia in Preeclampsia:
* Epidural in labour – there is   gradual onset of sympathetic
blockade ? it provides cardiovascular stability and therefore it
avoids neonatal depression.
* Epidural anesthesia may reduce the vasospasm and HTN – may
improve uteroplacental blood flow
* Regional anesthesia reduces the risk of  complications in the
airway and it avoids hemodynamic instability which is associated
with intubation.
* Some studies suggest neuraxial anesthesia
* Use of single shot spinal anesthesia is also controversial.
* In general anesthesia ,there is risk of difficult intubation due to
airway edema.
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* Neuraxial techniques is the preferred method, but contraindicated,
when coaguloapthy is present.
* When general anesthesia is given to patients who gets MgSO4,it
potentiates the action of succinyl choline.
* Sensitivity to agents like  non-depolarizing muscle relaxants is
increased.
* MgSO4 blunts the response to vasconstrictors and also inhibits the
release of catecholamine  after sympathetic stimulation.
* Prevention:various strategies are used in the prevention and
modificaton of preeclampsia severity.
Dietary manipulation includes low-salt in diet,  supplementation
of calcium, supplementation  with fish oil .
Salt restriction is found to be ineffective in preventing
preeclampsia.
Calcium supplementation : various studies shows that, low intake
of calcium has an increased risk of developing gestational hypertension.
Various trials  shows that calcium  supplementation
Is helpful only in women who is deficient in calcium.
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
51
It was believed that fatty acids of fish oil would prevent
atherogenesis  caused  by  inflammation,  but  randomized  trials  shows  no
such effects.
Antioxidants like vitamin c and vitamin E, helps to reduce
oxidative stress, but randamised trials shows, that there is no reduction in
the risk of preeclampsia, when antioxidants were supplemented, when
compared to placebo.
Low dose aspirin : clinical trials shows only limited effects in the
prevention of preeclampsia. aspirin inhibits  thromboxane A2 production
and its effects is only minimal  on production of prostacyclin.
Clinical trials shows that the relative risk is reduced by 10 percent,
to develop preeclampsia, preeclampsia superimposed on chronic
hypertension, preterm labour. Administration of low dose aspirin must be
individualized, to prevent recurrence of preeclampsia.
* Sethuram R, Kiran TS, Weerakkody AN  assessed, spot
protein/creatinine ratio as the diagnostic test for pre-eclampsia and
correlated it to the 24h urine protein. Patients were selected from
District General Hospital >24 weeks' gestation with hypertension
and >1+ proteinuria (n=32). The results of the test were correlated
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to 24hrs urine protein results using Pearson's correlation
coefficient. They found that Correlation was significant
(r(2)=0.82).The results were Sensitivity, 83%; specificity, 92%;
positive likelihood ratio, 10.3; negative likelihood ratio, 0.18. They
concluded that, spot PCR correlates well to the 24h urine protein
examination
* Laleh Eslamian1, Fariba Behnam1, Zahra Foroohesh Tehrani2,
Ashraf Jamal1 and Vajiheh Marsoosi1.
(26 Apr. 2009;) studied the  reliability of random urinary protein–
creatinine ratio  by using receiver operator characteristic (ROC) curve to
detect significant proteinuria  (300mg/day) using 24hrs Urine protein as a
gold standard).
The study concluded that Random urinary protein creatinine ratio
is a simple inexpensive and excellent alternative to 24h urine collection.
Therefore spot urine protein creatinine ratio is helpful in diagnosis
of  preeclampsia  and  suggested  to  use  it   as  a  pre  admission  test  in  PIH
cases.
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* Amita Sharma1, Pandey Kiran2, Bhagoliwal Ajai3 ( 3 August
2013);  Spot urine P/C ratio  and the 24- hour urine protein was
measured
The comparison between the spot P/C ratio and 24-hour urine
protein measurement was done. ROC curve analysis wasused  to analyse
data.
They found that there was a strong correlation between the spot
P/C ratio and 24-hour urine protein excretion (pearson’s correlation
coefficient r = 0.71; P < 0.0001).
The  optimal  cut  off  point  of  spot  P/C  ratio   was  0.25,  for  300
mg/24 h of protein excretion, with sensitivity and specificity of 69% and
75% respectively.
The study concluded that Spot urine P/C ratio is a quick and
reliable test which can be used as an alternative method for evaluation of
proteinuria for diagnosis of pre-eclampsia.
* Nahid Shahbazian, Farzaneh Hosseini-Asl (July 2008)
prospectively studied  81 pregnant women with preeclampsia for
proteinuria and observed the correlation between the spot P/C ratio
and 24-hour urine protein
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The optimal cutoff point  for spot P/C ratio was found to be 0.20
for 300 mg/24 h.
The sensitivity, specificity, positive predictive value, and negative
predictive value  was found to be 91.2%, 87.8%, 94.4%, and 96.8%,
respectively.
The spot P/C ratios less than 0.19  indicates a sensitivity of 100%
for exclusion of preeclampsia.
They concluded that Urine P/C ratio could be used for exclusion of
preeclampsia.
* Shahrzad, Mohammad Reza,(14 NOV 2006) compared random
urine protein to creatinine ratio (p:c ratio) and  24-h urine protein
excretion rate in pregnant women  suspicious  of pre-eclampsia.
The  study  was  conducted  on  100  pregnant  women   ? 20  weeks
gestation, of which 50 patients were suspected of having pre-eclampsia
and 50 were  selected as healthy pregnant women.
A  random  urine  p:c  ratio  and  a  24-h  urine  sample  for  protein
measurement were obtained. Results showed that all women suspected of
having pre-eclampsia had significant proteinuria.
With the cut-off ? 0.2 mg/mg the sensitivity was 94% and the
specificity of 96% . Using the same cut-off value in the normal pregnant
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women who were not thought to have pre-eclampsia, the sensitivity of the
test (p:c ratio) was 29% and the specificity was 87%.
Pearson's correlation coefficient was found to be  26 (P < 0.06).
Negative predictive value and positive predictive value were found to be
34% and 83%, respectively.
* Thomas L. Wheeler (5 July 2006) , studied the correlation between
spot urine protein to creatinine (P:C) ratios with 24 hour urine
collections for protein in women who was evaluated for
preeclampsia.
The study population was 126 patients admitted to evaluate for
preeclampsia. Correlation between the spot protein :creatinine ratio with
the 24 hour urine protein collections was calculated.
The result showed that there was strong correlation between
random spot P:C ratios and 24 hour urine protein levels (Pearson r =
0.88).
The optimal P:C cut-offs value was 0.21 (300 mg per 24 hours) and
3.0 (5000 mg per 24 hours). The study reported that P:C ratio of less than
0.21 (300 mg per 24 hours) had a negative predictive value (NPV) of
83.3% and a P:C ratio value < 3.0 (5000 mg per 24 hours) had 100%
NPV.
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AIM  OF THE STUDY
Primary objective:
Prediction of  Preeclampsia by spot  urinary Protein : Creatinine
ratio  in early pregnancy [ before 20 weeks of pregnancy].
Secondary objective:
To  find  the  Maternal  outcome   in  developing  Preeclampsia  and
Eclampsia.
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MATERIALS AND METHODS
STUDY DESIGN:
Prospective cross sectional study
STUDY PERIOD:
January 2013 to November 2013
INCLUSION CRITERIA :
Women with 16 to 20 wks of gestation with singleton pregnancy
both  Primi and Multigravida.
EXCLUSION CRITERIA:
* Patients with chronic hypertension
* Known case of renal disease
* Diabetes mellitus complicating pregnancy
* Heart disease complicating pregnancy
* Jaundice complicating pregnancy
* Gestational age >20 wks
* Patients with urinary tract infection
* Previous history of preeclampsia
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SAMPLE SIZE FOR FREQUENCY IN A POPULATION :
Population size (for finite population correction factor or fpc) (N) : 600
Hypothesized % frequency of outcome factor in the population (p):25%+/-5
Confidence limits as % of 100 (absolute +/-%) (d) : 5%
Design effect (for cluster surveys – DEFF) : 1
SAMPLE SIZE :
? N=(Z)2 [P] [1-P]/ d2
? Proportion of Preeclampsia=0.25[25%]
? (1.96)2 [0.25] [0.75]/[0.05]2  =288[300]
? Total no of samples=300
METHODOLOGY :
My study population included a total number of 300 antenatal
women who attented the antenatal clinic in the department of Obstetrics
and Gynaecology at kilpauk medical college. They were selected
according to inclusion and exclusion criteria.
Informed consent was obtained from each patient after explaining
about my study. A detailed history was obtained regarding her name, age,
height, prepregnancy weight, obstetric score, place of residence, socio
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economic class, past history of preeclampsia, family history  suggestive
of preeclampsia, associated comorbid conditions.
Her vitals were checked and basic investigations was taken.
Patients urine sample was collected and protein creatinine ratio was
estimated. protein estimation was done using pyrogalloll method,
creatinine estimation was done by modified jaffeys method and the ratio
was obtained between the two.
Patients were adviced to attend the antenatal clinic every two
weeks. In her follow up visit she was examined thoroughly, especially her
blood pressure, urine albumin was checked. Fetal well being was assessed
in each visit.
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RESULTS OF THE STUDY
The study group was grouped into two, depending upon the
development of preeclampsia, as normal cohort and preeclamptic cohort.
The variables taken into consideration in this study are, age group,
obstetric score, socio economic class, prepregnancy weight, body mass
index, urine spot protein creatinine ratio value.  For each variable Mean +
SD of all variables of interest were determined for preeclampsia cohort
and for normal cohort separately and difference was tested by chi-square
test.
The predictive values of urine protein creatinine ratio was analysed
using  pearson’s ROC curve.
Analysis was done by SPSS version 15.
Comparison of variables was done using chi-square test.
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TABLE - 1
RISK FACTORS ASSOCIATED WITH OCCURRENCE OF
PREECLAMPSIA
Cases
Valid Missing Total
N Percent N Percent N Percent
AGE GROUP *
OCCURRENCE  OF
PREECLAMPSIA 300 100.0% 0 .0% 300 100.0%
OBSTETRIC SCORE *
OCCURRENCE  OF
PREECLAMPSIA
300 100.0% 0 .0% 300 100.0%
COMORBID
CONDITIONS *
OCCURRENCE  OF
PREECLAMPSIA
300 100.0% 0 .0% 300 100.0%
SE CLASS *
OCCURRENCE  OF
PREECLAMPSIA 300 100.0% 0 .0% 300 100.0%
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TABLE - 2
AGE GROUP - OCCURRENCE  OF  PREECLAMPSIA
OCCURRENCE  OF
PREECLAMPSIA
0 1 Total
AGE
GROUP
1 Count 14 9 23
% within
OCCURRENCE  OF
PREECLAMPSIA
5.0% 42.9% 7.7%
2 Count 176 4 180
% within
OCCURRENCE  OF
PREECLAMPSIA
63.1% 19.0% 60.0%
3 Count 67 0 67
% within
OCCURRENCE  OF
PREECLAMPSIA
24.0% .0% 22.3%
4 Count 22 8 30
% within
OCCURRENCE  OF
PREECLAMPSIA
7.9% 38.1% 10.0%
Total Count 279 21 300
% within
OCCURRENCE  OF
PREECLAMPSIA
100.0% 100.0% 100.0%
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
63
TABLE – 3
OCCURRENCE OF PREECLAMPSIA AMONG VARIOUS AGE
GROUP
AGE
GROUP(YRS)
PREECLAMPTIC
COHORT
NORMAL COHORT
NO OF
CASES
%
NO OF
CASES
%
<20 9 42.9% 14 5%
21-25 4 19.0% 176 63.1%
26-30 0 0.0% 67 24.0%
31 AND
ABOVE
8 38.1% 22 7.9%
? Chi-square=65.652  p=0.000
? Age group distribution showed,42.9% of preeclamptic cohort and
5% of normal cohort belonged to age group less than 20 years.
? In the age group 31 and above ,38.1% developed preeclampsia
? It indicates that, preeclampsia is distributed and more common
among teenage pregnancy and elderly gravid
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FIGURE  – 8
AGE GROUP – DISTRIBUTION AMONG STUDY POPULATION
INFERENCE:
As ‘p’ value is 0.000,there is statistically significant between
preeclamptic cohort and normal cohort with regard to age group
0
20
40
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80
100
120
140
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200
Category 1 Category 2 Category 3 Category 4
normal cohort
preeclamptic cohort
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TABLE - 4
OBSTETRIC SCORE - OCCURRENCE  OF  PREECLAMPSIA
OCCURRENCE  OF
PREECLAMPSIA
0 1 Total
OBSTETRIC
SCORE
1 Count 146 17 163
% within
OCCURRENCE  OF
PREECLAMPSIA
52.3% 81.0% 54.3%
2 Count 93 1 94
% within
OCCURRENCE  OF
PREECLAMPSIA
33.3% 4.8% 31.3%
3 Count 32 1 33
% within
OCCURRENCE  OF
PREECLAMPSIA
11.5% 4.8% 11.0%
4 Count 6 2 8
% within
OCCURRENCE  OF
PREECLAMPSIA
2.2% 9.5% 2.7%
5 Count 2 0 2
% within
OCCURRENCE  OF
PREECLAMPSIA
.7% .0% .7%
Total Count 279 21 300
% within
OCCURRENCE  OF
PREECLAMPSIA
100.0% 100.0% 100.0%
? Chi-square=12.964           p=0.011
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TABLE – 5
PERCENTAGE DISTRIBUTION OF  PREECLAMPSIA AMONG
PRIMI GRAVIDA AND MULTI GRAVIDA
PARITY
PREECLAMPTIC
COHORT
NORMAL COHORT
NO OF
CASES %
NO OF
CASES
%
PRIMI 17 81% 146 52.3%
GRAVIDA 2 1 4.8% 93 33.3%
GRAVIDA 3 1 4.8% 32 11.5%
GRAVIDA 4 2 9.5% 6 2.2%
GRAVIDA 5 0 0.0% 2 0.7%
This study indicates statistical significance between normal cohort
and preeclamptic cohort.
Regarding parity,81% of preeclampsia occurred in primigravida.
About 9.5% of preeclampsia occurred in fourth gravid, but it
affected only 4.8% of gravid 2 and gravid 3.
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FIGURE -  9
OBSTETRIC SCORE – DISTRIBUTION OF PREECLAMPSIA
AMONG STUDY GROUP
? 0=normal cohort                  1=preeclamptic cohort
? INFERENCE:
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TABLE - 6
COMORBID CONDITIONS - OCCURRENCE  OF
PREECLAMPSIA
Total
COMORBID
CONDITIONS
0 Count 300
% within
OCCURRENCE  OF
PREECLAMPSIA
100.0%
Total Count 300
% within
OCCURRENCE  OF
PREECLAMPSIA
100.0%
Patients in the study group were selected without any comorbid
conditions, like chronic hypertension, renal disease, heart disease etc.
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TABLE - 7
SE CLASS - OCCURRENCE  OF  PREECLAMPSIA
OCCURRENCE  OF
PREECLAMPSIA
0 1 Total
SE CLASS 2 Count 1 0 1
% within OCCURRENCE  OF
PREECLAMPSIA
.4% .0% .3%
SE CLASS 4 Count 91 5 96
% within OCCURRENCE  OF
PREECLAMPSIA
32.6% 23.8% 32.0%
SE CLASS 5 Count 187 16 203
% within OCCURRENCE  OF
PREECLAMPSIA
67.0% 76.2% 67.7%
Count 279 21 300
About 67.7% of the pregnant women belonged to socioeconomic
class 5.Out of which,76.2% developed preeclampsia and 67% belonged to
normal cohort
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TABLE – 8
SE CLASS – PERCENTAGE DISTRIBUTION OF
PREECLAMPSIA
SE
CLASS
PREECLAMPTIC
COHORT NORMAL COHORT
NO OF
CASES %
NO OF
CASES %
2 0 0.0% 1 0.4%
4 5 23.8% 91 32.6%
5 16 76.2% 187 67.0%
FIGURE - 10
SE CLASS – DISTRIBUTION OF PREECLAMPSIA
0=normal cohort            1=preeclamptic cohort
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When SE class was taken into consideration,67% of normal cohort
and 76.2% of preeclamptic cohort occurred in the class 5,whereas,32.6%
of normal cohort and 23.8% of preeclamptic cohort belonged to class 4
SE class.
INFERENCE:
Since, the p- valve is 0.673, there is no statistical significance
between preeclamptic cohort and normal cohort with regard to
socioeconomic class.
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TABLE - 9
BMI GROUP - OCCURRENCE  OF  PREECLAMPSIA
Occurrence of Preeclampsia
0 1 Total
BMI
GROUP
1 Count 34 0 34
% within
OCCURRENCE  OF
PREECLAMPSIA
12.2% .0% 11.3%
2 Count 128 2 130
% within
OCCURRENCE  OF
PREECLAMPSIA
45.9% 9.5% 43.3%
3 Count 96 7 103
% within
OCCURRENCE  OF
PREECLAMPSIA
34.4% 33.3% 34.3%
4 Count 16 10 26
% within
OCCURRENCE  OF
PREECLAMPSIA
5.7% 47.6% 8.7%
5 Count 5 2 7
% within
OCCURRENCE  OF
PREECLAMPSIA
1.8% 9.5% 2.3%
Total Count 279 21 300
% within
OCCURRENCE  OF
PREECLAMPSIA
100.0% 100.0% 100.0%
? Chi-square=53.058                              p=0.000
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TABLE - 10
BMI - OCCURRENCE OF PREECLAMPSIA
BMI
PREECLAMPTIC
COHORT NORMAL COHORT
NO OF
CASES %
NO OF
CASES %
<18.5 0 0.0% 34 12.2%
18.5-24.9 2 9.5% 128 45.9%
25-29.9 7 33.3% 96 34.4%
30-35 10 47.6% 16 5.7%
35-40 2 9.5% 5 1.8%
? BMI of the study population was calculated according to her
prepregnant weight.
? Quetelet index was used to calculate the BMI.
? From the above table it is clear that, about 47.6% of preeclampsia
occurred in the moderately obese group.
? 33.3% of preeclamptic cohort and 34.4% of normal cohort, were
present in overweight group.
? In  women  with  normal  BMI  ,preeclampsia  occurred  in  9.5%  and
45.9% comes under normal cohort.
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?  My study population also included severely obese women and
about 9.5%  developed preeclampsia and 1.8% comes under
normal cohort.
FIGURE - 11
BMI - DISTRIBUTION OF PREECLAMPSIA AMONG STUDY
GROUP
INFERENCE:
? As p=0.000,there is statistical significance between, preeclamptic
cohort and normal cohort, with regard to BMI.
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FIGURE - 12
ROC CURVE - URINE SPOT PROTEIN CREATININE RATIO
URINE  SPOT PCR
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 Sensitivity: 85.7
 Specificity: 99.6
 Criterion : >0.45
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TABLE – 11
URINE SPOT PCR – OCCURRENCE OF PREECLAMPSIA
URINE
SPOT PCR
TOTAL PREECLAMPTIC
COHORT
NORMAL
COHORT
>0.3 21 18 3
0.2-0.29 54 2 52
<0.2 225 1 224
Area under the ROC curve (AUC) 0.964543
Standard Errora 0.0230
95% confidence intervalb 0.936806 to 0.982438
z statistic 20.192
Significance level P (Area = 0.5) <0.0001
The  above  table  & ROC,  infer that  there is  a  Good  Fit  in the
prediction  for  the  cut  off  value  >0.45  and   the   Area   Under  the   ROC
curve(AUC)  is  0.964543.Sensitivity is 87.5 and specificity is 99.6.It
indicates  Spot pcr  is the  good  indicator for prediction of Pre eclampsia.
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Area Under a Receiver Operating Characteristic Curve (ROC):
Total area under ROC curve is used as a single index for measuring
the performance a test. when the AUC is larger, the better is overall
performance of the medical test to correctly identify diseased and non-
diseased subjects. When the AUCs of two tests are equal, it represents
similar overall performance of tests but this does not necessarily mean
that both the curves are identical. It indicates that they may cross each
other.
? Regarding urine spot PCR values, when the cut off value is >0.45,
the sensitivity is 85.71%., specificity is 99.64%.
? When the cut  off  value is  >0.5,  the sensitivity of  urine spot  pcr  is
76.19% and the specificity is the same 99.64%.
? If the cut off value is reduced to 0.2, the sensitivity of the test
increases to 95.24%.
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TABLE – 12
MEAN DISTRIBUTION OF PREECLAMPSIA AMONG VARIOUS
VARIABLES
OCCURRENCE  OF
PREECLAMPSIA N Mean
AGE(YRS) 1 21 24.71
0 279 24.77
HT(CM) 1 21 152.48
0 279 152.18
WT(KG) 1 21 69.14
0 279 55.55
BMI 1 21 29.8481
0 279 88.5271
SAMPLE TAKEN
GA(WKS)
1 21 18.00
0 279 18.01
URINE  SPOT PCR 1 21 .73
0 278 .12
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TABLE – 13
OCCURRENCE OF PREECLAMPSIA – STANDARD DEVIATION
AMONG VARIOUS FACTORS
OCCURRENCE  OF
PREECLAMPSIA Std. Deviation
Std. Error
Mean
AGE(YRS) 1 5.596 1.221
0 3.412 .204
HT(CM) 1 5.810 1.268
0 6.175 .370
WT(KG) 1 8.873 1.936
0 11.422 .684
BMI 1 4.11899 .89884
0 1078.18279 64.54912
SAMPLE TAKEN
GA(WKS)
1 1.549 .338
0 1.373 .082
URINE  SPOT PCR 1 .482 .105
From this study, it was found that the following variables are
statistically significant.
? Age of the patient
? Obstetric score
? Socioeconomic class
? Prepregnancy weight of the patient and BMI
? Urine spot Protein creatinine ratio
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TABLE – 14
THE  FINAL OUTCOME OF THE STUDY
VARIABLE CHI-SQUARE
VALUE
P
AGE GROUP 65.652 0.000
PARITY 12.964 0.011
SE CLASS 0.791 0.673
BMI 53.058 0.000
URINE  SPOT PCR WITH SIGNIFICANT  P’=<0.0001
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SUMMARY
From this study it is found that, there is statistical significance
between  preeclamptic cohort and normal cohort with regard to following
variables :
- Age group
- Obstetric score
- Socioeconomic class
- BMI
- Urine PCR
* When age group was taken into consideration, about 42.9%
developed.
* Preeclampsia and 5% did not develop preeclampsia in the age
group <20  years.
* In the age group >30 years,38.1%  developed preeclampsia and
7.9% did not develop preeclampsia. There was statistical
significance between normal cohort and preeclamptic cohort.
* In my study about 81% preeclampsia occurred in primigravida and
only 4.8%  occurred in gravid 2 and gravid 3.
* About 9.5% of  preeclamptic cohort  and 2.2% of normal cohort
were present among gravid 4.
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* Among the people belonging to SE class 5,about 76.2% developed
* Preeclampsia and 23.8%  belonged to preeclamptic cohort in
women belonging to SE class 4.
* There is no statistical significance with regard to SE class.
* About 47.6% of preeclamptic cohort, were moderately obese
patients. In my study group, preeclampsia did not occur in
underweight persons.
* Only 9.5% of preeclampsia occurred in women with normal BMI
and 33.3% in overweight individual. The variable BMI is also
statistically significant.
* The cut off value for urine PCR was taken as >0.45,to predict
preeclampsia with 85.71% sensitivity and 99.64% specificity.
When the cut off value is reduced the sensitivity increases.
* The Area under the ROC curve ,for urine PCR is 0.964.
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DISCUSSION
? Our study population included 300 antenatal women who attended
antenatal out- patient department. Among  them ,urine spot PCR
predicted preeclampsia in 21 patients.
? Out  of  21  patients,18  women  had  urine  spot   PCR  cut  off  value
>0.45.
? Only 2 patients developed  preeclampsia ,in the cut off value
between 0.2 to 0.29.
? In the cut off value <0.2 , only one patient developed preeclampsia.
? It was also found that, preeclampsia is more common among
women with increased prepregnant weight and BMI > 25.
? Our study also reported that, primigravida and age group less than
20 years were more prone to develop preeclampsia.
? Our study is supported by the analysis done by Laleh Eslamian1,
Fariba Behnam1, Zahra Foroohesh Tehrani2, Ashraf Jamal1, and
Vajiheh Marsoosi1 (26 Apr. 2009;). The study showed  a cut off
value of 0.22mg/mg for protein creatinine ratio and it  best
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predicted significant proteinuria with sensitivity, specificity,
positive and negative predictive values of 87%, 92.6%, 90.6% and
89.3% respectively.
? Amita Sharma1, Pandey Kiran2, Bhagoliwal Ajai3 ( 3 August
2013);  Spot urine P/C ratio  and the 24- hour urine protein was
measured.
? They found that there was a strong correlation between the spot
P/C ratio and 24-hour urine protein excretion (pearson’s correlation
coefficient r = 0.71; P < 0.0001).
? The  optimal  cut  off  point  of  spot  P/C  ratio   was  0.25,  for  300
mg/24 h of protein excretion, with sensitivity and specificity of
69% and 75% respectively.
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CONCLUSION
After investigating and analysing the study, it was found that,
?  Urine spot PCR is a simple method and rapid test to predict
preeclampsia. when cut of value is more, the specificity increases.
? From this study it is concluded that when the cut off value for urine
spot PCR is >0.45, the sensitivity is 85.71% and specificity is
99.64%.
? Urine spot PCR can be used to predict preeclampsia in early
gestation itself, so that the patient can be kept under proper
surveillance, with more frequent antenatal check up,and to detect
the complications earlier to prevent maternal and fetal morbidity
and mortality.
? Urine spot PCR can be used at the level of primary health centre, to
detect the high risk pregnancies and refer them to the tertiary care
centre at the earliest.
? It was also found that, more number of preeclampsia occurred in
women with increased prepregnancy weight, with raised BMI.
overweight and obese women developed preeclampsia more than
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the normal individual therefore, proper weight reduction will
reduce the risk of developing preeclampsia.
? Urine spot PCR can be used to predict preeclampsia
with a single random midstream urine sample when
compared to 24 hrs urine protein estimation and
routine dipstick method.
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KEY  TO  MASTER  CHART
BMI - Body mass index
Ht - Height
PCR - Protein creatinine ratio
SE Class - Socioeconomic Class
s.no - Serial number
wt - Weight
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PROFORMA
NAME:                                             AGE:                      OPNO:
ADDRESS: PHONE NO:
OBSTETRIC  SCORE:                               LMP:                     EDD:
COMPLAINTS:
PREVIOUS H/O  PREECLAMPSIA:
FAMILY H/O PREECLAMPSIA:
ASST COMORBID FACTORS:
HEIGHT:                                 WEIGHT:                             BMI:
GENERAL EXAMINATION:
PALLOR:YES/NO         ICTERUS:YES/NO                   PEDAL
EDEMA:YES/NO
BLOOD  PRESSURE:
SYSTEMIC EXAMINATION:
                  CARDIOVASCULAR SYSTEM:
                  RESPIRATORY SYSTEM:
GESTATIONAL AGE BY,
                    PER ABDOMEN EXAMINATION:
                   USG:
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INVESTIGATIONS:
HB%:                                    TC: PLATELET COUNT:
URINE R/E:    ALBUMIN:                     SUGAR:             DEPOSITS:
RFT:                 SUGAR:                   UREA:                  CREATININE:
LFT:
         S.BILIRUBIIN:
         SGOT:
         SGPT:
         S.ALP:
        S.URIC ACID:
        TOTAL PROTEIN:
         ALBUMIN:
         GLOBULIN:
URINE   PCR:
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